1. Home
  2. XNCR

XNCR

Xencor Inc.

Logo Xencor Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.

Founded: 1997 Country:
United States
United States
Employees: N/A City: PASADENA
Market Cap: 1.3B IPO Year: 2013
Target Price: $35.71 AVG Volume (30 days): 714.8K
Analyst Decision: Strong Buy Number of Analysts: 7
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.08 EPS Growth: N/A
52 Week Low/High: $16.49 - $30.21 Next Earning Date: 05-06-2024
Revenue: $168,338,000 Revenue Growth: 2.28%
Revenue Growth (this year): -43.44% Revenue Growth (next year): 52.46%

Share on Social Networks: